Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
Sign Up
Log in
I-Mab banner

I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 3.98 USD 0.51% Market Closed
Market Cap: $325m
Write Note Create Alert Ask AI

I-Mab
Investor Relations

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

Show more
Loading
IMAB
S&P 500
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2023
Call Date
Aug 17, 2023
AI Summary
Q2 2023

Revenue Drop: I-Mab reported revenue of $2.7 million in H1 2023, down from $7.7 million in H1 2022, mainly from collaborations with AbbVie and HI-Bio.

Strong Balance Sheet: The company ended June 30, 2023, with $414.6 million in cash, which management says is sufficient to fund strategic plans.

Strategic Refocus: I-Mab is prioritizing two oncology assets, uliledlimab and givastomig, for global development, and is shifting to become a US-based biotech company.

Positive Clinical Milestone: Eftansomatropin alfa, a long-acting human growth hormone, met its Phase 3 primary endpoint and showed non-inferiority to Norditropin, supporting plans for a 2024 BLA filing in China.

Cost Control: Both R&D and administrative expenses fell significantly year-over-year, reflecting ongoing streamlining.

Stock Buyback: The board authorized up to $40 million in share repurchases.

Upcoming Data Catalysts: Key readouts and regulatory submissions expected in 2024, including for lead assets in oncology and rare diseases.

Key Financials
Revenue
$2.7 million
Cash, cash equivalents, restricted cash, and short-term investment
$414.6 million
R&D Expenses
$61.6 million
Administrative Expenses
$33.8 million
Adjusted Net Loss
$87.5 million
Shares Outstanding
190 million
Stock Repurchase Program
$40 million authorized
Eftansomatropin alfa Phase 3 Mean Annualized Height Velocity (AHV)
10.76 cm/year
Earnings Call Recording
Open Full Analysis Open Transcript
Other Earnings Calls
2023
Q2

Management

Dr. Xi-Yong Fu M.B.A., Ph.D.
CEO & Director
No Bio Available
Mr. Skelton Joseph
Chief Financial Officer
No Bio Available
Mr. Tianyi Zhang
Vice President of Investor Relations
No Bio Available
Dr. Fernando J. Salle´s Ph.D.
Senior VP and Head of U.S. & EU Business Development
No Bio Available
Dr. Louie Naumovski M.D., Ph.D.
Interim Chief Medical Officer
No Bio Available
Dr. Phillip Dennis M.D., Ph.D.
Chief Medical Officer
No Bio Available
Mr. Tyler Ehler
Senior Director of Investor Relations
No Bio Available

Contacts

Address
SHANGHAI
Shanghai
55Th-56Th Floor, New Bund Center, 555 West Haiyang Road, Pudong District
Contacts
+862160578000.0
www.i-mabbiopharma.com
sparklesyt

See Also

Summary
IMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMAB stock valuation using valuation multiples.
Wall Street Estimates
IMAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 325,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett